PLUS1
247.98
0.20 (0.08%)
0.20 (0.08%)
Upgrade to Real-Time
Premarket
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Level 1 Starter
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Vertex Pharmaceuticals Inc | VRTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Low Price | High Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 247.78 | 0.00 | 0.00 | 0.00 | 247.78 | 07:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 243.30 | 251.98 | 8.68 | 3.44% | - | - |
| Stock Trades | Traded Volume | Average Volume | 52 Week Range |
|---|---|---|---|
| 1 | 2 | 1,428,808 | 163.681 - 249.85 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 07:00:04 | 2 | $ 247.98 | USD |
Vertex Pharmaceuticals Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 63.72B | 257.15M | $ 2.10B | 4.51 | 53.20 | 254.95M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Vertex Pharmaceuticals News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/19/2020 | 16:41 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/19/2020 | 16:39 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/19/2020 | 16:38 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/19/2020 | 16:37 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/19/2020 | 16:36 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/19/2020 | 16:34 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 2/19/2020 | 16:33 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VRTX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 241.41 | 249.85 | 238.55 | 244.26 | 1,090,405 | 6.37 | 2.64% |
| 1 Month | 235.00 | 249.85 | 223.01 | 237.67 | 1,351,000 | 12.78 | 5.44% |
| 3 Months | 220.39 | 249.85 | 214.55 | 229.24 | 1,228,155 | 27.39 | 12.43% |
| 6 Months | 187.04 | 249.85 | 165.23 | 206.82 | 1,212,333 | 60.74 | 32.47% |
| 1 Year | 186.06 | 249.85 | 163.681 | 192.40 | 1,202,940 | 61.72 | 33.17% |
| 3 Years | 88.34 | 249.85 | 84.39 | 163.12 | 1,445,512 | 159.44 | 180.48% |
| 5 Years | 112.55 | 249.85 | 71.46 | 136.34 | 1,538,688 | 135.23 | 120.15% |
Vertex Pharmaceuticals Description
| Vertex Pharmaceuticals discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex's pipeline also includes therapies for cancer, pain, inflammatory diseases, influenza, and other rare diseases. |
